RECRUITING

Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea

Talk to us

Conditions

Obstructive Sleep Apnea

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a safety and efficacy trial for a Slow Wave, Inc. UASD oral appliance for the treatment of Obstructive Sleep Apnea. This trial will recruit 60-80 participants through our IRB partner. Each participant will take pre-trial and post trail sleep studies and be measured before, throughout and after the trial for Apnea-Hypopnea Index (AHI), Oxygen Desaturation Index (ODI), pulse rate to determine level of sleep improvement while wearing the device. Safety will also be measured through survey, dental exams and adverse events monitoring. Patients will wear an O2 monitoring ring throughout the study and upload results daily. Primary Objectives will evaluate AHI and ODI between sleep studies. Secondary outcomes will compare the daily ring data to these two sleep studies to evaluate changes over time. Patients will have the opportunity to complete daily diaries on their sleep experiences.

Official Title

Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea

Quick Facts

Study Start:2024-10-01
Study Completion:2025-05-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06519149

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * • Provision of signed and dated informed consent form
  2. * Unable to tolerate or decline positive airway pressure therapy
  3. * Absence of markedly enlarged tonsils, defined as 3+ or 4+ according to the Brodsky classification
  4. * Able to protrude tongue ≥20mm beyond maxillary incisors
  5. * No uncontrolled nasal obstruction (must be able to breathe through nose)
  6. * Stable medication regimen for ≥1 month
  7. * Stated willingness to comply with all study procedures and availability for the duration of the study
  8. * Male or female, of any race, aged 18-70 years (inclusive)
  9. * If diagnosed with uncomplicated Mild to moderate, moderate to severe OSA (i.e., AHI \>5, \<30 h-1); where uncomplicated is defined by the absence of:
  10. * Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia). Examples of such conditions include significant cardiopulmonary disease, potential respiratory muscles weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use.
  11. * Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia).
  12. * Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT.
  13. * Body mass index (BMI) \< 35 kg/m2
  14. * Neck circumference \< 45 cm
  15. * Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 \> 82%
  16. * Mandibular range of motion \> 5 mm in protrusive direction
  17. * Adequate dentition, as determined by the site dentist
  18. * Must have a smart phone able to download 02 ring app
  1. * • Inability to breathe through the nose comfortably
  2. * Presence of \> 25% Central Sleep Apnea (CSA)
  3. * Severe OSA above AHI \>40
  4. * Uncontrolled sleep disorder such as narcolepsy, chronic insomnia, restless legs syndrome, or REM behavior disorder
  5. * Presence of positional obstructive sleep apnea per Cartwright's definition (Ratio of respiratory events in the supine to nonsupine position greater than 2:1)
  6. * History of surgery intended to alter anatomy for the correction of OSA, such as uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), or tongue/hyoid suspension.
  7. * History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy within the previous 6 months
  8. * Presence of hypoglossal nerve stimulation device
  9. * Use of CPAP or OAT within the two weeks prior to the screening HSAT
  10. * Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgeries; UPPP, MMA, tongue/hyoid suspension)
  11. * Loose teeth or advanced periodontal disease
  12. * Teeth extractions/Presence of a dental post implanted less than 12 months
  13. * Removable dentures
  14. * History of temporomandibular joint disorder (TMJ)
  15. * Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with ≥ 3 oral hypertensive agents
  16. * Presence of congestive heart failure (NYHA Class IV), persistent/permanent atrial fibrillation, or acute coronary artery disease (STEMI/NSTEMI/USA) in the past 30 days.
  17. * Presence of neuromuscular diseases e.g. myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome and muscular dystrophy, or hypoventilation disorders which results in shallow breathing during sleep and/or cyanosis of the fingers/toes.
  18. * Presence of pulmonary disease resulting in significant desaturation, e.g., severe chronic obstructive pulmonary disease, interstitial lung disease (SaO2 nadir of 87%), or pulmonary hypertension
  19. * History of cerebrovascular incident within the last 12 months
  20. * Use of pacemaker or other life supporting device
  21. * Anticipated change in body weight \> 5% during the study period
  22. * Participation in other studies that could interfere with the study protocol

Contacts and Locations

Study Contact

Bill S Morris
CONTACT
5124663977
bmorris@slowwave.net
Wayne R Wagner
CONTACT
2817875589
wwagner@slowwave.net

Principal Investigator

Matthew Jepson, MD
PRINCIPAL_INVESTIGATOR
St. David's HealthCare
Nirman Koladia, MD
STUDY_DIRECTOR
Clinical Research Consultant

Study Locations (Sites)

Austin Heart Research
Austin, Texas, 78705
United States

Collaborators and Investigators

Sponsor: Slow Wave, Inc.

  • Matthew Jepson, MD, PRINCIPAL_INVESTIGATOR, St. David's HealthCare
  • Nirman Koladia, MD, STUDY_DIRECTOR, Clinical Research Consultant

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-01
Study Completion Date2025-05-30

Study Record Updates

Study Start Date2024-10-01
Study Completion Date2025-05-30

Terms related to this study

Additional Relevant MeSH Terms

  • Obstructive Sleep Apnea